Company intelligence / Profile preview

Abcam

Cambridge, England, United Kingdomabcam.com ↗

Ownership: Public · ABCM
Employees: ~1450
Development stage: Commercial

Overview

Abcam does not develop therapeutics but provides highly validated antibodies and reagents that support drug discovery and diagnostics globally. Their products are widely cited in scientific literature and used by over 750,000 researchers worldwide

Therapeutic areas: Other
Modalities: AntibodyRecombinant proteinPeptidesCell line
Industry: Chemicals & Materials

Drug pipeline

2 assets

sevacizumab

Phase 2

Indications: Colorectal Cancer, Fallopian Tube Carcinoma

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborates with life science organizations for co-development of antibodies as key reagents in drug discovery and diagnostics.Partners include over 400 suppliers globally for sourcing additional products

Financials

Market cap: $5.5B
Total revenue: $203.2M
Enterprise value: $5.7B

Beyond the preview

Go deeper on Abcam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abcam.

Explore the full profile